Comparison Study of Thalidomide Versus Calcium Dibutyryladenosine Cyclophosphate in the Treatment of Moderate to Severe Psoriasis Vulgaris
Objective To compare the clinical efficacy of thalidomide(THD)versus calcium dibutyryladenosine cyclophosphate(CDC)in the treatment of moderate to severe psoriasis vulgaris.Methods A total of 120 patients with moderate to severe psoriasis vulgaris admitted to the Third Affiliated Hospital of Nantong University from March 2020 to July 2022 were selected and divided into the THD group and the CDC group by the random number table method,with 60 cases in each group.The patients in the two groups were given topical urea cream at the rash site,on this basis,the patients in the THD group were given Thalidomide Tablets orally,while the patients in the CDC group were given intravenous drip of Calcium Dibutyryladenosine Cyclophosphate for Injection.Both groups were treated continuously for five months.Results The total effective rate in the THD group was 98.33%,which was significantly higher than 86.67%in the CDC group(P<0.05).After treatment,the body surface area(BSA),the psoriasis area and severity index(PASI)in the THD group were significantly lower than those in the CDC group;the total cholesterol(TC),triglyceride(TG)and uric acid(UA)levels were significantly lower than those in the CDC group;the serum basic fibroblast growth factor(bFGF),vascular endothelial growth factor(VEGF),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6)and interleukin-17(IL-17)levels were significantly lower than those in the CDC group(P<0.05).The incidence of adverse reactions in the THD group was 3.33%,which was significantly lower than 20.00%in the CDC group(P<0.05).The readmission rates in the THD group within three and six months of treatment were significantly lower than those in the CDC group(P<0.05).Conclusion Compared with CDC,THD in the treatment of moderate to severe psoriasis vulgaris is more effective in improving serological indexes and relieving inflammatory reactions at skin lesions.
thalidomidecalcium dibutyryladenosine cyclophosphatemoderate to severe psoriasis vulgarisserological indexinflammatory factorclinical efficacy
国家科技期刊平台
NSTL
万方数据
维普
